HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?
Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organi...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2012
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23952
- Acceso en línea:
- https://repository.urosario.edu.co/handle/10336/23952
- Palabra clave:
- Nevirapine
Nonnucleoside reverse transcriptase inhibitor
Zidovudine
Blood toxicity
Brazil
Cd4 lymphocyte count
Central america
Follow up
Gene mutation
Gene sequence
Geographic distribution
Heterosexual male
Highly active antiretroviral therapy
Human
Human immunodeficiency virus 1 infection
Mexico
Prevalence
Rash
Review
Risk factor
Socioeconomics
South and central america
Venezuela
Virus transmission
World health organization
Caribbean region
Female
Guidelines as topic
Hiv infections
Hiv-1
Humans
Latin america
Male
Prevalence
Caribbean
Drug resistance
Genotype
Hiv-1
Latin america
Naive
viral
missense
Drug resistance
Mutation
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_71a6f7382741ba78b95fd46ba78faace |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/23952 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
3e55916f-82d6-4efb-8ace-19e4bab6bfe0-17ef2b174-79ad-4db9-aeaa-7493403d9977-1f1f5fc82-68b8-4245-85be-ccfaaaa08370-1e0288969-4908-446e-b7f8-e9388878fc5c-1175b76c7-4c59-4c59-99e3-de4b980e2095-1693c47de-32d7-4155-a17d-efe0ac1f9631-107a5da01-1828-47eb-befd-3d38811325e1-12020-05-26T00:07:00Z2020-05-26T00:07:00Z2012Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO). Consequently, our aim was to review all relevant studies on transmitted drug resistance in Latin America and the Caribbean countries, to analyze its levels, to identify the frequency of transmitted drug resistance mutations, and to put these results in the context of the local Latin American and Caribbean countries settings. A systematic search of Spanish, Portuguese, and English literature was performed in databases and international conferences for the period June 1999 to May 2011. In addition, sequences were downloaded from the Los Alamos and Stanford databases and the transmitted drug resistance was reanalyzed according to the WHO Surveillance Drug Resistance Mutation list 2009. In total, 50 articles, 27 abstracts, and 1,922 patients were included. The resistance varied geographically, but most of the countries have reached the WHO threshold of 5% of resistance. According to the sequences available in public databases, the overall prevalence in Latin America and the Caribbean countries for the period 1996-2009 was 7.7% and by region it was 4.3% for the Caribbean, 3.9% for Mexico, 9.4% for Brazil, 10.5% for the Andean region and 4.9% for the Southern Cone. For the last four investigated years (2006-2009), the information was restricted to Brazilian and Venezuelan studies and revealed an overall transmitted drug resistance of 10%. Throughout the study period, limited information was available for the Caribbean and Central American countries. These findings support the need for developing comprehensive surveys of transmitted drug resistance in these regions.application/pdf11396121https://repository.urosario.edu.co/handle/10336/23952eng267No. 4256AIDS ReviewsVol. 14AIDS Reviews, ISSN:11396121, Vol.14, No.4 (2012); pp. 256-267https://app.dimensions.ai/details/publication/pub.1078664397Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURNevirapineNonnucleoside reverse transcriptase inhibitorZidovudineBlood toxicityBrazilCd4 lymphocyte countCentral americaFollow upGene mutationGene sequenceGeographic distributionHeterosexual maleHighly active antiretroviral therapyHumanHuman immunodeficiency virus 1 infectionMexicoPrevalenceRashReviewRisk factorSocioeconomicsSouth and central americaVenezuelaVirus transmissionWorld health organizationCaribbean regionFemaleGuidelines as topicHiv infectionsHiv-1HumansLatin americaMalePrevalenceCaribbeanDrug resistanceGenotypeHiv-1Latin americaNaiveviralmissenseDrug resistanceMutationHIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Pineda-Peña A.-C.Bello D.-C.Sussmann O.Vandamme A.-M.Vercauteren J.Van Laethem K.Gómez-López A.10336/23952oai:repository.urosario.edu.co:10336/239522022-05-02 07:37:14.710715https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
title |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
spellingShingle |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? Nevirapine Nonnucleoside reverse transcriptase inhibitor Zidovudine Blood toxicity Brazil Cd4 lymphocyte count Central america Follow up Gene mutation Gene sequence Geographic distribution Heterosexual male Highly active antiretroviral therapy Human Human immunodeficiency virus 1 infection Mexico Prevalence Rash Review Risk factor Socioeconomics South and central america Venezuela Virus transmission World health organization Caribbean region Female Guidelines as topic Hiv infections Hiv-1 Humans Latin america Male Prevalence Caribbean Drug resistance Genotype Hiv-1 Latin america Naive viral missense Drug resistance Mutation |
title_short |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
title_full |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
title_fullStr |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
title_full_unstemmed |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
title_sort |
HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know? |
dc.subject.keyword.spa.fl_str_mv |
Nevirapine Nonnucleoside reverse transcriptase inhibitor Zidovudine Blood toxicity Brazil Cd4 lymphocyte count Central america Follow up Gene mutation Gene sequence Geographic distribution Heterosexual male Highly active antiretroviral therapy Human Human immunodeficiency virus 1 infection Mexico Prevalence Rash Review Risk factor Socioeconomics South and central america Venezuela Virus transmission World health organization Caribbean region Female Guidelines as topic Hiv infections Hiv-1 Humans Latin america Male Prevalence Caribbean Drug resistance Genotype Hiv-1 Latin america Naive |
topic |
Nevirapine Nonnucleoside reverse transcriptase inhibitor Zidovudine Blood toxicity Brazil Cd4 lymphocyte count Central america Follow up Gene mutation Gene sequence Geographic distribution Heterosexual male Highly active antiretroviral therapy Human Human immunodeficiency virus 1 infection Mexico Prevalence Rash Review Risk factor Socioeconomics South and central america Venezuela Virus transmission World health organization Caribbean region Female Guidelines as topic Hiv infections Hiv-1 Humans Latin america Male Prevalence Caribbean Drug resistance Genotype Hiv-1 Latin america Naive viral missense Drug resistance Mutation |
dc.subject.keyword.eng.fl_str_mv |
viral missense Drug resistance Mutation |
description |
Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO). Consequently, our aim was to review all relevant studies on transmitted drug resistance in Latin America and the Caribbean countries, to analyze its levels, to identify the frequency of transmitted drug resistance mutations, and to put these results in the context of the local Latin American and Caribbean countries settings. A systematic search of Spanish, Portuguese, and English literature was performed in databases and international conferences for the period June 1999 to May 2011. In addition, sequences were downloaded from the Los Alamos and Stanford databases and the transmitted drug resistance was reanalyzed according to the WHO Surveillance Drug Resistance Mutation list 2009. In total, 50 articles, 27 abstracts, and 1,922 patients were included. The resistance varied geographically, but most of the countries have reached the WHO threshold of 5% of resistance. According to the sequences available in public databases, the overall prevalence in Latin America and the Caribbean countries for the period 1996-2009 was 7.7% and by region it was 4.3% for the Caribbean, 3.9% for Mexico, 9.4% for Brazil, 10.5% for the Andean region and 4.9% for the Southern Cone. For the last four investigated years (2006-2009), the information was restricted to Brazilian and Venezuelan studies and revealed an overall transmitted drug resistance of 10%. Throughout the study period, limited information was available for the Caribbean and Central American countries. These findings support the need for developing comprehensive surveys of transmitted drug resistance in these regions. |
publishDate |
2012 |
dc.date.created.spa.fl_str_mv |
2012 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:07:00Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:07:00Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.issn.none.fl_str_mv |
11396121 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/23952 |
identifier_str_mv |
11396121 |
url |
https://repository.urosario.edu.co/handle/10336/23952 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
267 |
dc.relation.citationIssue.none.fl_str_mv |
No. 4 |
dc.relation.citationStartPage.none.fl_str_mv |
256 |
dc.relation.citationTitle.none.fl_str_mv |
AIDS Reviews |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 14 |
dc.relation.ispartof.spa.fl_str_mv |
AIDS Reviews, ISSN:11396121, Vol.14, No.4 (2012); pp. 256-267 |
dc.relation.uri.spa.fl_str_mv |
https://app.dimensions.ai/details/publication/pub.1078664397 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167640749375488 |